Allergan Sues Ajanta to Block Copy of Bystolic Hypertension Drug

Allergan said Ajanta’s proposed generic version of a treatment for high blood pressure infringes a patent for Bystolic.

• Allergan is seeking a court order blocking copies until the patent has expired, and to collect cash compensation if copies are made before then, according to the complaint filed July 2 in federal court in Wilmington, Delaware
• Patent expires in December 2021, according to supplemental filing
• Bystolic had U.S. sales of $128.3 million during the first three months of 2019, down from $132.8 million during the same period in 2018, Allergan said May 7
• AbbVie recently agreed to pay $63 billion to ...